Noria Therapeutics, Inc.
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Noria Therapeutics, Inc.
Bayer Saddles Up For Bicycle Radioconjugate Pact
The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.
Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium And Macropa Platforms
Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
Company Information
- Industry
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
-
- PSMA Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice